Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vaccine and skin testing properties of two avirulent Mycobacterium bovis mutants with and without an additional esat-6 mutation.

Tuberculosis (Edinburgh, Scotland) - 1 Jan 2003

Collins D M, Kawakami R P, Wards B J, Campbell S, de Lisle G W

Abstract excerpt

SETTING: Molecular techniques are now available to develop new live tuberculosis vaccines by producing avirulent strains of the Mycobacterium tuberculosis complex with known genes deleted. OBJECTIVES: Determine if removal of esat-6 from new live tuberculosis vaccines with known attenuating mutations affects their vaccine efficacy and if it could enable the development of discriminating diagnostic tests. DESIGN:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Bacterial
Share to BCG Vaccine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guinea Pigs

Share to Mycobacterium bovis

Share to Skin Tests

Share to Spleen

Share to Vaccines, Attenuated

Share to Vaccines, Synthetic

Source

Identifiers

PMID: 14623166
DOI: 10.1016/s1472-9792(03)00074-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vaccine and skin testing properties of two avirulent Mycobacterium bovis mutants with and without an additional esat-6 mutation.PMID 14623166Read ↗

New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex.Semantic proximity Read ↗

BCG Vaccines: Their mechanisms of attenuation and impact on safety and protective efficacySemantic proximity Read ↗

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines <i>Mycobacterium bovis</i> BCG and <i>Mycobacterium microti</i>Semantic proximity Read ↗

Mycobacterium bovis mutant in the virulence factors PhoP, ESAT-6 and CFP-10 persisted in mouse organs after a year post-vaccination.Semantic proximity Read ↗

Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCGSemantic proximity Read ↗

Production of avirulent mutants of Mycobacterium bovis with vaccine properties by the use of illegitimate recombination and screening of stationary-phase cultures.Semantic proximity Read ↗

BCG--different strains, different vaccines?Semantic proximity Read ↗

BCG VaccinesSemantic proximity Read ↗

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.Semantic proximity Read ↗

Impaired fitness of Mycobacterium africanum despite secretion of ESAT-6.Semantic proximity Read ↗

The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosisSemantic proximity Read ↗

Newly attenuated Mycobacterium bovis mutants as vaccines against bovine tuberculosis, particularly for possums.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.